Previous 10 |
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Johnson & Johnson Acquires Rights To A Drug That Treats Rare Forms Of Cancer News: Recently, Johnson & Johnson ( JNJ ) announced that it had ...
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. If you missed it, I recently p...
Editor's note: Seeking Alpha is proud to welcome Joseph Heglin as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Tivozanib ...
If you want to have a better performance than the crowd, you must do things differently from the crowd. - Value Investor (Sir John Templeton) Amid the bear market that is hitting bioscience stocks lately, we strongly believe that investors should increase their research due diligence and...
The company's TIVO-3 trial to compare tivozanib (FOTIVDA®) to sorafenib met its primary endpoint of demonstrating a statistically significant benefit in progression-free survival (PFS). More news on: AVEO Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, ...
- First and Only Positive Phase 3 Study in Third- and Fourth-Line RCC - - Primary Endpoint Shows 44% Improvement in Median PFS and 26% Reduction in Risk of Progression or Death (HR=0.74, p=0.02) for Tivozanib Compared to Sorafenib - - Data for Secondary Endpoint of Overall Surviva...
News, Short Squeeze, Breakout and More Instantly...
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committe...
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders ...
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO...